Mesenkia Therapeutics AB

ABActive

Org 5594437021Kyrkogårdsgatan 11, 753 10 UppsalaResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2023 · 2 years old1-4 employees

Overview Financials People & ownership Related companies

Mesenkia Therapeutics AB is a Swedish AB based in Uppsala, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2023, the company reported revenue of SEK 0 in its latest annual filing.

Revenue 2024

SEK 0

EBITDA margin

—

Net profit 2024

SEK -1,1M

Key ratios

See full ratios →

65.4%

This company

20242024

2.9×

This company

20242024

-215.3%

This company

20242024

EBITDA — year on year

SEK millions

Key figures

Annual report 2024

Revenue	SEK 0	—
EBITDA	SEK -1,1M	—
Net profit	SEK -1,1M	—
Total assets	SEK 501K	—
Equity	SEK 327K	—
Employees	—	—

Contact

Address

Kyrkogårdsgatan 11, 753 10 Uppsala

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Frequently asked questions

What is the Org number of Mesenkia Therapeutics AB?

Mesenkia Therapeutics AB is registered with Bolagsverket / SCB under Org 5594437021.

Who is the CEO of Mesenkia Therapeutics AB?

Moa Elisabet Fransson is the CEO of Mesenkia Therapeutics AB, in role since 2025.

Who is the chairman of Mesenkia Therapeutics AB?

Johan Lars Fredrik Lund chairs the board of Mesenkia Therapeutics AB, in role since 2025.

Where is Mesenkia Therapeutics AB headquartered?

Mesenkia Therapeutics AB's registered address is Kyrkogårdsgatan 11.

Mesenkia Therapeutics AB

Key ratios

EBITDA — year on year

Key figures

Company information

Contact

Frequently asked questions

More on Mesenkia Therapeutics AB

Key ratios

EBITDA — year on year

Key figures

Company information

Contact

Frequently asked questions

More on Mesenkia Therapeutics AB